{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:37:44Z","timestamp":1781602664783,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Veterans Affairs Fellowship Program in Medical Informatics"},{"name":"Canadian Institute for Health Research Doctoral Fellowship"},{"name":"Cubist pharmaceuticals"},{"name":"Merck Canada"},{"name":"AstraZeneca"},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alere"},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Astellas"},{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Biom\u00e9rieux"},{"name":"GSK"},{"name":"Astellas"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Keryx biopharmaceuticals"},{"name":"Genkyotex"},{"name":"Pharmalink"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.cmi.2017.07.012","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T03:02:47Z","timestamp":1500951767000},"page":"110-117","source":"Crossref","is-referenced-by-count":22,"title":["Susceptibilities of clinical Clostridium difficile isolates to antimicrobials: a systematic review and meta-analysis of studies since 1970"],"prefix":"10.1016","volume":"24","author":[{"given":"N.","family":"Khanafer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Daneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Simor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vanhems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Samore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cmi.2017.07.012_bib1","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.02176-12","article-title":"Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection","volume":"57","author":"Brown","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.012_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/dkt477","article-title":"Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis","volume":"69","author":"Slimings","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.cmi.2017.07.012_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/cid\/cir301","article-title":"Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection","volume":"53","author":"Stevens","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2017.07.012_bib4","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1086\/521859","article-title":"Antimicrobial-associated risk factors for Clostridium difficile infection","volume":"46","author":"Owens","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.cmi.2017.07.012_bib5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1469-0691.2009.03048.x","article-title":"In\u00a0vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden","volume":"16","author":"Noren","year":"2010","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.cmi.2017.07.012_bib6","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1128\/AAC.00479-06","article-title":"In\u00a0vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada","volume":"50","author":"Bourgault","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.cmi.2017.07.012_bib7","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/496986","article-title":"Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec","volume":"41","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.cmi.2017.07.012_bib8","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.012_bib9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2017.07.012_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0895-4356(89)90168-6","article-title":"Meta-analysis in medical research: strong encouragement for higher quality in individual research efforts","volume":"42","author":"O'Rourke","year":"1989","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.cmi.2017.07.012_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.cmi.2017.07.012_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/45.suppl_3.71","article-title":"Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in\u00a0vitro","volume":"45","author":"Higgins","year":"2000","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"20","key":"10.1016\/j.cmi.2017.07.012_bib13","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/sim.7336","article-title":"Intermediate and advanced topics in multilevel logistic regression analysis","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.cmi.2017.07.012_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tree.2008.10.008","article-title":"Generalized linear mixed models: a practical guide for ecology and evolution","volume":"24","author":"Bolker","year":"2009","journal-title":"Trends Ecol Evol"},{"key":"10.1016\/j.cmi.2017.07.012_bib15","series-title":"Medical microbiology","author":"Baron","year":"1996"},{"issue":"Pt 9","key":"10.1016\/j.cmi.2017.07.012_bib16","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1099\/jmm.0.058875-0","article-title":"Antimicrobial susceptibility of animal and human isolates of Clostridium difficile by broth microdilution","volume":"62","author":"Pirs","year":"2013","journal-title":"J\u00a0Med Microbiol"},{"issue":"1","key":"10.1016\/j.cmi.2017.07.012_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhin.2005.01.020","article-title":"Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK","volume":"61","author":"John","year":"2005","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.cmi.2017.07.012_bib18","series-title":"Foye's principles of medicinal chemistry","author":"Foye","year":"2013"},{"issue":"Pt 5","key":"10.1016\/j.cmi.2017.07.012_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1099\/jmm.0.041053-0","article-title":"Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007","volume":"61","author":"Karlowsky","year":"2012","journal-title":"J\u00a0Med Microbiol"},{"issue":"1","key":"10.1016\/j.cmi.2017.07.012_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/mdr.2006.12.23","article-title":"Genotypic and phenotypic analysis of Clostridium difficile correlated with previous antibiotic exposure","volume":"12","author":"Samore","year":"2006","journal-title":"Microb Drug Resist"},{"issue":"Suppl.\u00a06","key":"10.1016\/j.cmi.2017.07.012_bib21","first-page":"vi13","article-title":"European Surveillance of Antimicrobial Consumption (ESAC): outpatient penicillin use in Europe (1997-2009)","volume":"66","author":"Versporten","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2017.07.012_bib22","doi-asserted-by":"crossref","first-page":"g5493","DOI":"10.1136\/bmj.g5493","article-title":"Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis","volume":"349","author":"Currie","year":"2014","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.cmi.2017.07.012_bib23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","article-title":"Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data","volume":"14","author":"Van Boeckel","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"1332","key":"10.1016\/j.cmi.2017.07.012_bib24","first-page":"45","article-title":"Molecular epidemiology and susceptibility profiles of Clostridium difficile in New Zealand, 2009","volume":"124","author":"Roberts","year":"2011","journal-title":"New Zealand Med J"},{"issue":"2","key":"10.1016\/j.cmi.2017.07.012_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/030079908X253735","article-title":"Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence","volume":"24","author":"Deshpande","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.cmi.2017.07.012_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijmm.2013.02.016","article-title":"Molecular epidemiology and resistance profiles of Clostridium difficile in a tertiary care hospital in Spain","volume":"303","author":"Weber","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.cmi.2017.07.012_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.anaerobe.2014.07.007","article-title":"First clinical and microbiological characterization of Clostridium difficile infection in a Croatian University Hospital","volume":"30","author":"Novak","year":"2014","journal-title":"Anaerobe"},{"key":"10.1016\/j.cmi.2017.07.012_bib28","unstructured":"The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Available at: www.eucast.org."},{"issue":"9","key":"10.1016\/j.cmi.2017.07.012_bib29","first-page":"CD004610","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhea in adults","author":"Nelson","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.cmi.2017.07.012_bib30","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1128\/AAC.06257-11","article-title":"Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens","volume":"56","author":"Snydman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.cmi.2017.07.012_bib31","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkn313","article-title":"Emergence of reduced susceptibility to metronidazole in Clostridium difficile","volume":"62","author":"Baines","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.cmi.2017.07.012_bib32","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/AAC.17.4.695","article-title":"In\u00a0vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis","volume":"17","author":"Dzink","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.cmi.2017.07.012_bib33","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/jcp.33.10.1002","article-title":"Antimicrobial susceptibilities of Clostridium difficile","volume":"33","author":"Shuttleworth","year":"1980","journal-title":"J\u00a0Clin Pathol"},{"issue":"1","key":"10.1016\/j.cmi.2017.07.012_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijantimicag.2012.03.015","article-title":"Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea","volume":"40","author":"Kim","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.cmi.2017.07.012_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1348-0421.1982.tb00150.x","article-title":"Antimicrobial susceptibility of Clostridium difficile from different sources","volume":"26","author":"Nakamura","year":"1982","journal-title":"Microbiol Immunol"},{"issue":"10","key":"10.1016\/j.cmi.2017.07.012_bib36","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1086\/428835","article-title":"Prevalence of the ermB gene in Clostridium difficile strains isolated at a university teaching hospital from 1987 through 1998","volume":"40","author":"Tang-Feldman","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.cmi.2017.07.012_bib37","first-page":"383","article-title":"Studies on the resistance of Clostridium difficile to antimicrobial agents","volume":"267","author":"Wust","year":"1988","journal-title":"Zentralbl Bakteriol Mikrobiol Hyg A"},{"issue":"6","key":"10.1016\/j.cmi.2017.07.012_bib38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.anaerobe.2010.09.002","article-title":"Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains","volume":"16","author":"Huang","year":"2010","journal-title":"Anaerobe"},{"issue":"10","key":"10.1016\/j.cmi.2017.07.012_bib39","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/jac\/dkr292","article-title":"Multidrug resistance in European Clostridium difficile clinical isolates","volume":"66","author":"Spigaglia","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.cmi.2017.07.012_bib40","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/599224","article-title":"Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection","volume":"48","author":"Herpers","year":"2009","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1730383X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X1730383X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T03:12:39Z","timestamp":1589771559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X1730383X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1198743X1730383X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.07.012","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}